Please assess the completion status of the following clinical trial:

Trial Title: Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 years old~* Men or women~* Women post-menopausal or with ongoing contraception~* Diagnosis of acquired hemophilia A~* Patient must be insured~* Patient has provided written informed consent prior to enrollment~* Patient compliant~Exclusion Criteria:~* Congenital hemophilia~* Ongoing treatment with prednisone \> 20mg/d （or equivalent corticosteroid doses） more than 1 month~* Ongoing treatment with prednisone \>0.7mg/kg（or equivalent corticosteroid doses） more than 10 days~* Pregnant and breastfeeding women~* Allergy to steroid~* Immunosuppressive agents treatment within 30 days~* Serum transaminase and bilirubin greater than 1.5 times the upper limit of normal value~* Hepatitis B surface antigen or hepatitis C antibody or HIV antibody (I + II) or syphilis antibody positive~* Patients with diabetes, hypertension, glaucoma, peptic ulcer, herpes zoster, pulmonary infection and so on, who should not be treated with glucocorticoids~* Patients with poor compliance~* Those who can not take contraceptive measures during the test period~* Patient who is considered by the investigator not suitable for clinical study~* Thrombocytopenia~* Leucocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Steroid+Rituximab (Type: EXPERIMENTAL): Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
- Steroid +Cyclophosphamide (Type: ACTIVE_COMPARATOR): Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).